Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862096 | 0.86 | MAOA (0.47) | ADORA3ADORA2ARAB9AALDH1A1ALOX5 | |
| SCHEMBL10967059 | 0.85 | MAPT (0.46) | ADORA3RAB9AALDH1A1ALOX5NPC1 | |
| SCHEMBL4297486 | 0.81 | KMT2A (0.51) | ADORA3ADORA2ARAB9AALDH1A1MEN1 | |
| SCHEMBL8321136 | 0.81 | RAD51 (0.43) | ADORA3ADORA2ARAB9AALDH1A1ALOX5 | |
| SCHEMBL20222411 | 0.81 | MEN1 (0.55) | ADORA3RAB9AALDH1A1NPC1MEN1 | |
| SCHEMBL3451092 | 0.81 | ALOX5 (0.44) | ADORA3ADORA2ARAB9AALDH1A1ALOX5 | |
| SCHEMBL1012879 | 0.79 | KIF11 (0.44) | RAB9AALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL9013563 | 0.79 | DYRK1A (0.50) | ADORA3RAB9AALDH1A1NPC1MEN1 | |
| SCHEMBL3451384 | 0.78 | KDM4E (0.60) | ADORA2ARAB9AALDH1A1ALOX5NPC1 | |
| SCHEMBL600729 | 0.78 | RAD51 (0.44) | ADORA3ADORA2AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744175-B2 | Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment | INDUS PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150056192-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | INDUS PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20070021451-A1 | Method for preventing or treating neurologic damage after spinal cord injury | HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7091206-B2 | Process for producing pyrimidine derivative and intermediate thereof | NIPPON SHINYAKU CO., LTD (JP) | 2006-08-15 | — | — | US | disclosed |
| EP-1318146-B1 | PROCESS FOR PRODUCING PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | NIPPON SHINYAKU CO LTD (JP) | 2005-02-23 | — | — | EP | disclosed |
| EP-0781766-B1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040023985-A1 | Process for producing pyrimidine derivative and intermediate thereof | NIPPON SHINYAKU CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| CN-1118454-C | Heterocyclic derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2003-08-20 | — | — | CN | disclosed |
| EP-1318146-A1 | PROCESS FOR PRODUCING PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | Nippon Shinyaku Co., Ltd. (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6191149-B1 | DRUG FOR CEREBROVASCULAR DISEASE | NIPPON SHINYAKU, CO., LTD. (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5945426-A | PREVENT NEURONAL DEATH | NIPPON SHINYAKU CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0781766-A1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021451-A1 | Method for preventing or treating neurologic damage after spinal cord injury | SMN1; SMN2, AQP4, GAP43 | ADORA3 2205/4885ADORA2A 2635/4885RAB9A 2019/4885 |
| US-20150056192-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | TOP2A, HMGB1, TOP2B | ADORA3 1437/4885ADORA2A 590/4885RAB9A 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.